

# Iain B Mcinnes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5488448/publications.pdf>

Version: 2024-02-01

134  
papers

25,739  
citations

36303

51  
h-index

17592

121  
g-index

141  
all docs

141  
docs citations

141  
times ranked

27220  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tyrosine kinase 2 and Janus kinase signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 148-157.	1.2	51
2	Does Age Matter in Psoriatic Arthritis? A Narrative Review. <i>Journal of Rheumatology</i> , 2022, 49, 1085-1091.	2.0	13
3	A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. <i>Rheumatology</i> , 2022, 61, 1783-1794.	1.9	31
4	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.9	26
5	Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 475-485.	5.6	41
6	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 359-369.	0.9	47
7	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. <i>RMD Open</i> , 2022, 8, e002195.	3.8	11
8	Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. <i>RMD Open</i> , 2022, 8, e002074.	3.8	27
9	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1184-1192.	5.6	5
10	Dissecting the molecular control of immune cell accumulation in the inflamed joint. <i>JCI Insight</i> , 2022, 7, .	5.0	2
11	Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. <i>RMD Open</i> , 2022, 8, e002049.	3.8	8
12	Psoriatic arthritis from a mechanistic perspective. <i>Nature Reviews Rheumatology</i> , 2022, 18, 311-325.	8.0	49
13	OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study. <i>Rheumatology</i> , 2022, 61, .	1.9	0
14	Levelling the playing field of RMD research across Europe to address patients' needs: the emerging EULAR Research Centre. <i>RMD Open</i> , 2022, 8, e002456.	3.8	0
15	Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 604-616.	5.6	48
16	Stromal coactivation markers do not confer pathogenic activity in tendinopathy. <i>Translational Sports Medicine</i> , 2021, 4, 268-279.	1.1	5
17	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 185-193.	0.9	79
18	IL-23 orchestrating immune cell activation in arthritis. <i>Rheumatology</i> , 2021, 60, iv4-iv15.	1.9	9

#	ARTICLE	IF	CITATIONS
19	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.9	37
20	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 1227-1239.	27.0	143
21	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. <i>Rheumatology</i> , 2021, 60, 5337-5350.	1.9	18
22	P173â€fEfficacy and safety of upadacitinib versus placebo and adalimumab in patients with active PsA and inadequate response to non-biologic DMARDs (SELECT-PSA-1): a double-blind, randomised controlled phase III trial. <i>Rheumatology</i> , 2021, 60, .	1.9	0
23	P174â€fUpadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. <i>Rheumatology</i> , 2021, 60, .	1.9	1
24	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. <i>RMD Open</i> , 2021, 7, e001679.	3.8	19
25	Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1494-1497.	0.9	33
26	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. <i>Rheumatology</i> , 2021, 60, 2109-2121.	1.9	44
27	Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. <i>New England Journal of Medicine</i> , 2021, 385, 628-639.	27.0	156
28	Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	18
29	Immune-mediated inflammatory disease therapeutics: past, present and future. <i>Nature Reviews Immunology</i> , 2021, 21, 680-686.	22.7	106
30	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001845.	3.8	11
31	Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001080.	3.0	21
32	Tofacitinib inhibits CD4 T cell polarisation to Th1 during priming thereby leading to clinical impact in a model of experimental arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
33	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. <i>Rheumatology and Therapy</i> , 2021, 8, 1677-1691.	2.3	1
34	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to diseaseâ€associated psychological morbidity. <i>British Journal of Dermatology</i> , 2020, 182, 130-137.	1.5	52
35	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2020, 47, 539-547.	2.0	16
36	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	2.0	10

#	ARTICLE	IF	CITATIONS
37	Attenuation of Dupuytren's fibrosis via targeting of the STAT1 modulated IL-13R $\alpha$ 1 response. <i>Science Advances</i> , 2020, 6, eaaz8272.	10.3	16
38	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020, 395, 1496-1505.	13.7	178
39	The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 349-356.	4.3	14
40	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.9	609
41	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.9	205
42	Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1126-1136.	13.7	206
43	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	13.7	122
44	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. <i>Cardiovascular Research</i> , 2020, 116, 1666-1687.	3.8	1,074
45	In Human Autoimmunity, a Substantial Component of the B Cell Repertoire Consists of Polyclonal, Barely Mutated IgG+ve B Cells. <i>Frontiers in Immunology</i> , 2020, 11, 395.	4.8	16
46	GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOLimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naïve patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 490-498.	0.9	41
47	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
48	Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 281-291.	1.1	5
49	Molecular imaging of inflammation - Current and emerging technologies for diagnosis and treatment. , 2020, 211, 107550.		45
50	A Vision for Cytokine Biology with 20/20 Clarity. <i>Function</i> , 2020, 2, zqaa042.	2.3	1
51	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	1.6	77
52	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	2.9	766
53	Responsiveness of Serum C-reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2019, 71, 1660-1669.	5.6	13
54	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naïve patients with psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 497-510.	1.4	15

#	ARTICLE	IF	CITATIONS
55	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naïve Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1458-1461.	2.0	11
56	Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 441-444.	3.0	2
57	Rheumatoid arthritis and depression: an inflammatory perspective. <i>Lancet Psychiatry</i> , 2019, 6, 164-173.	7.4	238
58	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. <i>Rheumatology</i> , 2019, 58, 197-205.	1.9	68
59	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 988-995.	0.9	41
60	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	30.5	1,441
61	Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 579-588.	0.9	26
62	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018, 20, 47.	3.5	117
63	P059 Ex vivo comparison of baricitinib, upadacitinib, filgotinib and tofacitinib for cytokine signalling in human leukocyte subpopulations. , 2018, , .		1
64	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
65	Model answers: Rational application of murine models in arthritis research. <i>European Journal of Immunology</i> , 2018, 48, 32-38.	2.9	19
66	In vivo multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. <i>Theranostics</i> , 2018, 8, 6195-6209.	10.0	56
67	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1107-1123.	1.4	35
68	The extending scope of kinase inhibition in immune diseases. <i>Lancet</i> , 2018, 392, 2328-2331.	13.7	2
69	Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018, 20, 113.	3.5	24
70	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. <i>Scientific Reports</i> , 2017, 7, 40473.	3.3	32
71	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
72	Elevated ACKR2 expression is a common feature of inflammatory arthropathies. <i>Rheumatology</i> , 2017, 56, 1607-1617.	1.9	9

#	ARTICLE	IF	CITATIONS
73	Managing rheumatic and musculoskeletal diseases “ past, present and future. Nature Reviews Rheumatology, 2017, 13, 443-448.	8.0	117
74	Guidelines for the use of flow cytometry and cell sorting in immunological studies<sup>*</sup>. European Journal of Immunology, 2017, 47, 1584-1797.	2.9	505
75	Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1949-1952.	0.9	63
76	Targeting danger molecules in tendinopathy: the HMGB1/TLR4 axis. RMD Open, 2017, 3, e000456.	3.8	33
77	MicroRNA29a Treatment Improves Early Tendon Injury. Molecular Therapy, 2017, 25, 2415-2426.	8.2	51
78	Wounds that heal and wounds that donâ€™t âˆ™ The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis. Seminars in Cell and Developmental Biology, 2017, 61, 41-50.	5.0	31
79	RHEUMATOID ARTHRITIS: PATHOGENESIS204.â€fCHARACTERIZATION OF SYNOVIUM TISSUES MACROPHAGE OF RHEUMATOID ARTHRITIS PATIENTS. Rheumatology, 2017, 56, .	1.9	0
80	Assessment of murine collagen-induced arthritis by longitudinal non-invasive duplexed molecular optical imaging. Rheumatology, 2016, 55, kev361.	1.9	22
81	Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigenâ€™Presenting Cells. Arthritis and Rheumatology, 2016, 68, 627-638.	5.6	23
82	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 2016, 75, 1043-1050.	0.9	167
83	Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open, 2016, 2, e000287.	3.8	46
84	OP0008â€™..Synovial Fibroblast Proliferation Is Enhanced by Microna-223 Delivery through Monocyte-Derived Microparticles. Annals of the Rheumatic Diseases, 2016, 75, 55.3-56.	0.9	0
85	A10.07â€™..The kinetic cytokine/chemokine secretory profile in surgical models of osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, A75.2-A75.	0.9	0
86	Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis, 2016, 254, 167-171.	0.8	20
87	Ustekinumab Treatment and Improvement of Physical Function and Healthâ€™Related Quality of Life in Patients With Psoriatic Arthritis. Arthritis Care and Research, 2016, 68, 1812-1822.	3.4	27
88	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Annals of the Rheumatic Diseases, 2016, 75, 1984-1988.	0.9	131
89	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nature Communications, 2016, 7, 12970.	12.8	97
90	MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis. Rheumatology, 2016, 55, 2056-2065.	1.9	84

#	ARTICLE	IF	CITATIONS
91	A1.10â€¦The GM-CSF/CCL17 axis in the rheumatoid synovial environment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A4.2-A5.	0.9	0
92	FR10051â€¦In Vivo Imaging To Characterise The Specificity, Function and Behavior of The CD4+ T Cells Initiating Articular Inflammation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 444.2-444.	0.9	0
93	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 461.	1.9	22
94	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016, 43, 1713-1717.	2.0	77
95	Mast Cells Contribute to Porphyromonas gingivalis-induced Bone Loss. <i>Journal of Dental Research</i> , 2016, 95, 704-710.	5.2	25
96	A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune Diseases. <i>Cell Host and Microbe</i> , 2016, 19, 400-408.	11.0	25
97	Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain. <i>FASEB Journal</i> , 2016, 30, 54-65.	0.5	121
98	Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation. <i>Rheumatology</i> , 2016, 55, 120-132.	1.9	32
99	Psoriatic arthritis: embracing pathogenetic and clinical heterogeneity?. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 9-11.	0.8	10
100	Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. <i>Pharmacological Reviews</i> , 2015, 67, 280-309.	16.0	266
101	Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin Î² Receptors. <i>Immunity</i> , 2015, 42, 1100-1115.	14.3	179
102	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2015, 386, 1137-1146.	13.7	722
103	The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens. <i>Immunology and Cell Biology</i> , 2015, 93, 167-176.	2.3	18
104	Cellular imaging in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015, 11, 357-367.	8.0	14
105	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015, 373, 1329-1339.	27.0	629
106	Periodontitis in the absence of B cells and specific anti-bacterial antibody. <i>Molecular Oral Microbiology</i> , 2015, 30, 160-169.	2.7	46
107	The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4+ T cell-priming capacity of dendritic cells. <i>Rheumatology</i> , 2015, 54, 169-177.	1.9	15
108	Elevated interleukin-10: A new cause of dyslipidemia leading to severe HDL deficiency. <i>Journal of Clinical Lipidology</i> , 2015, 9, 81-90.	1.5	38

#	ARTICLE	IF	CITATIONS
109	Tightening Up? Impact of Musculoskeletal Ultrasound Disease Activity Assessment on Early Rheumatoid Arthritis Patients Treated Using a Treat to Target Strategy. <i>Arthritis Care and Research</i> , 2014, 66, 19-26.	3.4	52
110	Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 605-624.	3.3	32
111	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 990-999.	0.9	576
112	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 349-356.	0.9	308
113	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1000-1006.	0.9	255
114	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet, The</i> , 2013, 382, 780-789.	13.7	688
115	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 382, 1705-1713.	13.7	518
116	Efficacy and safety of mavrimumab in subjects with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1445-1452.	0.9	149
117	Back to the future: oral targeted therapy for RA and other autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2013, 9, 173-182.	8.0	106
118	Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. <i>Nature Reviews Rheumatology</i> , 2013, 9, 513-523.	8.0	212
119	Metabolic Profiling Predicts Response to Anti-Tumor Necrosis Factor Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1448-1456.	6.7	121
120	OP0272...Abatacept is highly effective in inhibiting T cell priming but fails to induce T cell tolerance after primary antigen encounter. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 148.2-148.	0.9	1
121	IL-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E <sub>2</sub> . <i>British Journal of Pharmacology</i> , 2013, 169, 90-101.	5.4	81
122	The Pathogenesis of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2011, 365, 2205-2219.	27.0	4,200
123	Arthritis in space and time – To boldly go!. <i>FEBS Letters</i> , 2011, 585, 3640-3648.	2.8	5
124	Breach of self tolerance in rheumatoid arthritis: a role for Th17 effector T cells?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A50-A50.	0.9	0
125	Tumour necrosis factor blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1281-1285.	0.9	53
126	Golimumab, a new human tumor necrosis factor antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009, 60, 976-986.	6.7	547



#	ARTICLE	IF	CITATIONS
127	Does practice mirror the evidence base in the treatment of rheumatoid arthritis?. <i>Clinical Rheumatology</i> , 2009, 28, 961-970.	2.2	1
128	Interleukin-18: a therapeutic target in rheumatoid arthritis?. <i>Arthritis Research</i> , 2005, 7, 38.	2.0	51
129	Inducing Experimental Arthritis and Breaking Self-Tolerance to Joint-Specific Antigens with Trackable, Ovalbumin-Specific T Cells. <i>Journal of Immunology</i> , 2004, 173, 151-156.	0.8	52
130	A Novel Therapeutic Approach Targeting Articular Inflammation Using the Filarial Nematode-Derived Phosphorylcholine-Containing Glycoprotein ES-62. <i>Journal of Immunology</i> , 2003, 171, 2127-2133.	0.8	196
131	Selective Expression and Functions of Interleukin 18 Receptor on T Helper (Th) Type 1 but not Th2 Cells. <i>Journal of Experimental Medicine</i> , 1998, 188, 1485-1492.	8.5	330
132	Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor- $\alpha$ production in rheumatoid arthritis. <i>Nature Medicine</i> , 1997, 3, 189-195.	30.7	711
133	The role of interleukin-15 in cell migration and activation in rheumatoid arthritis. <i>Nature Medicine</i> , 1996, 2, 175-182.	30.7	463
134	Tofacitinib inhibits CD4 T cell polarisation to Th1 during priming thereby leading to clinical impact in a model of experimental arthritis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0